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Abstract
Background: Type A influenza viruses are contagious and even life-threatening if left untreated. So far, no broadly
protective vaccine is available due to rapid antigenic changes and emergence of new subtypes of influenza virus. In
this study, we exploited bioinformatics tools in order to design a subunit chimeric vaccine from the antigenic and
highly conserved regions of HA and M2 proteins of H7N9 subtype of influenza virus. We used mucosal adjuvant
candidates, including CTxB, STxB, ASP-1, and LTB to stimulate mucosal immunity and analyzed the combination of
HA2, M2e, and the adjuvant. Furthermore, to improve the antigen function and to maintain their three-dimensional
structure, 12 different linkers including six rigid linkers and six flexible linkers were used. The 3D structure model
was generated using a combination of homology and ab initio modeling methods and the molecular dynamics of
the model were analyzed, either.
Results: Analysis of different adjuvants showed that using CtxB as an adjuvant, results in higher overall vaccine
stability and higher half-life among four adjuvant candidates. Fusion of antigens and the CTxB in the form of M2e-
linker-CTxB-linker-HA2 has the most stability and half life compared to other combination forms. Furthermore, the
KPKPKP rigid linker showed the best result for this candidate vaccine among 12 analyzed linkers. The changes in
the vaccine 3D structure made by linker insertion found to be negligible, however, although small, the linker
insertion between the antigens causes the structure to change slightly. Eventually, using predictive tools such as
Ellipro, NetMHCpan I and II, CD4episcore, CTLpred, BepiPred and other epitope analyzing tools, we analyzed the
conformational and linear epitopes of the vaccine. The solubility, proteasome cleavage sites, peptidase and
potential chemical cutters, codon optimization, post translational modification were also carried out on the final
vaccine.
Conclusions: It is concluded that M2e-Linker-CTxB-Linker-HA2 combination of chimeric vaccine retains its 3D
structure and antigenicity when KPKPKP used as linker and CTxB used as adjuvant.
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Background
Influenza viruses belong to a family of RNA viruses,
Orthomyxoviridae, that are categorized as types A, B, C,
and Thogotovirus, which among them, only type A and B
are clinically relevant for humans disease [1]. One of the
deadliest pandemics in history is the 1918 H1N1 flu virus.
The pandemic, which spread worldwide, claimed the lives
of nearly 50 million people [2]. Influenza A and B have
both HA (hemagglutinin) and NA (neuraminidase) pro-
teins that are expressed on the surface of the virus. So far,
based on HA and NA surface antigens, 18 HA subtypes
and 11 NA subtypes have been observed for type A influ-
enza viruses that are theoretically expected to generate
198 potential new viral subtypes [3]. The M2 antigen of
the influenza A virus is also a surface protein that acts as a
tetrameric ion channel pump on the surface of the virus.
This activity is carried out after the virus entry into the
cell and attaching to endosomes to regulate the pH of the
virus capsid and pump the protons via a pH-inducible
proton transport mechanism [4]. The HA surface antigen
also creates a stalk structure at the virus surface that binds
the virus capsid to the host cell surface and allows the
virus to enter the host cell by the receptor-binding
method [5, 6]. Many studies have shown that both HA
and M2 proteins are immunogenic for their host. How-
ever, various modifications have been utilized to enhance
their immunogenicity and production of neutralizing anti-
bodies against these two proteins [7, 8].
There is always the concern that highly pathogenic
subtypes of type A influenza viruss, including H5 and
H7, may become more virulent to humans by reassort-
ment with other subtypes and result in increased
human-to-human transmissibility. Therefore, we need a
quick and inexpensive vaccination system to deal with
such threats. Several vaccination strategies have been de-
veloped for the influenza virus today, including inacti-
vated and attenuated viruses, viral vector-based vaccines
as well as DNA vaccines. Until now, only inactivated and
live-attenuated vaccines have been used clinically. How-
ever, there are some safety concerns about these vac-
cines, such as the reassortment of inactivated viruses
with other viruses and the possibility of producing a high
pathogenic new subtypes in the human body. In
addition, the conventional production methods of the in-
fluenza vaccine in chicken egg cause allergic reactions in
the recipient’s body. Furthermore, the presence of retro-
viruses in eggs raises the concern that these retroviruses
may affect inactivated influenza viruses [9, 10]. In
addition to inactivated and attenuated vaccines, many
studies have been conducted on the development of
third-generation vaccines based on viral vectors. How-
ever, the possibility of incorporating these vectors into
the genome and causing genetic abnormalities and ma-
lignancies actually prevents the expanding of such
vaccines [11]. Another type of vaccine that is receiving a
great deal of attention is subunit vaccines. Today, these
vaccines are produced by biotechnology methods, in-
cluding recombinant DNA technology [12]. These vac-
cines are produced in various expression systems, such
as the E. coli (prokaryotic expression system) or
eukaryotic expression systems such as yeast [13], HEK-
293 and CHO cell lines [14] as well as plant cells [12].
Due to the antigenic property of HA, NA, and M2e
proteins, various studies have been done on the de-
velopment of a subunit vaccine against influenza virus
based on these proteins [15]. In addition to these
proteins, NP and M1 have also been used to develop
subunit vaccines [16].
Nowadays, bioinformatics tools have come to the aid
of biology, biotechnology, and medical researchers to
perform various in-silico analysis before conducting any
experimental and laboratory research [17]. Obviously,
with the analysis, the quality and quantity of empirical
experiments will be much improved, and these experi-
ments will be conducted rationally, based on the infor-
mation obtained from bioinformatics analysis. Various
bioinformatics tools can be used in the development of a
vaccine [18, 19]. In our previous studies, bioinformatics
analyses were performed before in vitro development of
the chimeric vaccine candidate for the three anthrax,
shigellosis, and cholera diseases [12]. Before the expres-
sion of the vaccine in a host by biotechnology tech-
niques, bioinformatics analyses were conducted to
optimize the gene construct in terms of its stability and
half-life as well as to retain the third structure and epi-
topes intact [20].
Similarly, the aim of this study was to conduct a bio-
informatics analysis of a vaccine candidate containing
HA antigen and M2 antigen conserved region with
CTxB.
Results
Selecting the antigen combination and appropriate
adjuvant
The sequence information of antigens and adjuvants are
shown in Table S1. The Tm (melting temperature) and Ti
(melting temperature index) of antigenic fragments (calcu-
lated by http://tm.life.nthu.edu.tw/index.htm) showed in
Table S2.
ProtParam server was used to find which combination
of these antigens and which adjuvant could result in the
most stable structure and longest half-life. As shown in
Table 1, the results of the analysis of the various combi-
nations, show that the best adjuvant is CTxB. The lower
the instability index (II), the higher the stability of the
protein, i.e., if II of a given protein is calculated above
40, the protein is considered to be unstable. When the
HA2 antigen is placed in the N-terminal region of fusion
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proteins, the lowest instability index (II = 32.45) is ob-
tained. The two combinations CMH (C = CTxB, M =
M2e and H =HA2) and MCH, both have the lowest II,
indicating their stability. In addition they have the high-
est half-life index (30 h). However, because M2e is a
small antigenic region and in many cases is referred to
be a conserved epitopic region, we chose the M2e-
CTxB-HA2 (MCH) combination (to place M2e at the N-
terminal of fusion protein).
For other adjuvants, most of them showed unstable
combinations (II index above 40). For example, all com-
binations using LTB and STxB adjuvants showed an II
Table 1 Results of analysis of different combinations of antigens with different adjuvants predicted by ProtParam server
Adjuvant Fusion protein II Aliphatic Index GRAVY Half-life (hrs/mammalian)
CTxB MHC 32.78 76.15 0.459 30
MCH 32.45 76.15 0.459 30
HCM 32.78 76.15 0,459 30
CMH 32.45 76.15 0.459 30
CHM 32.78 76.15 0.459 30
HMC 32.78 76.15 0.459 30
ASP-1 MHA 39.17 34.55 0.758 4.4
MAH 38.74 34.55 0.758 4.4
AMH 38.74 34.55 0.758 4.4
AHM 39.17 34.55 0.758 4.4
HAM 39.17 34.55 0.758 30
HMA 39.17 34.55 0.758 30
LTB HML 41.62 35.90 0.847 30
HLM 42.03 35.90 0.847 30
LHM 42.03 35.90 0.847 4.4
LMH 41.51 35.90 0.847 4.4
Mhl 41.62 35.90 0.847 4.4
MLH 41.51 35.90 0.847 4.4
STxB SHM 42.75 34.09 0.783 4.4
SMH 42.14 34.09 0.783 4.4
HSM 42.75 34.09 0.783 30
HMS 42.37 34.09 0.783 30
MHs 42.37 34.09 0.783 4.4
MSH 42.14 34.09 0.783 4.4
Table 2 Analysis of different linkers using ProtParam server
Linker Sequence II of the fusion protein Aliphatic Index Gravy
Flexible linkers LF1 (G8) GGGGGGGG 35.08 74.92 −0.455
LF2 (G4S) GGGGS 32.45 76.15 −0.459
LF3 (G4S)2 GGGGSGGGGS 33.82 74.12 −0.459
LF4 GSAGSAAGSGEF 29.26 74.92 −0.425
LF5 KESGSVSSEQLAQFRSLD 34.65 77.08 −0.487
LF6 EGKSSGSGSESKST 32.26 72.57 −0.537
Rigid Linkers LR1 EAAAK 31.55 77.80 −0.456
LR2 A (EAAAK)2AA 30.06 77.68 −0.419
LR3 (XP)n = APAPAP 35.88 77.38 −0.440
LR4 (XP)n = EPEPEP 35.63 75.74 .527
LR5 (XP)n:KPKPKP 28.63 75.74 −0.533
LR6 (XP)n: GPGP 30.32 76.57 −0.470
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index above 40, indicating that their fusion proteins are
unstable. As for the ASP-1 adjuvant also shown, the cal-
culated II indeed is less than 40, but all of their combi-
nations showed an II near 40 (II = 39), which was much
higher than that of CTxB adjuvant. These results dem-
onstrate that the CTxB fusion proteins is more stable
compared to other adjuvants.
Selection of linker
Since the natural structures of antigens are crucial for
their antigenecity, we investigated the effect of linker ap-
plication using Protparam server. Table 2 presents the re-
sults of the linker analysis using Protparam server. As
shown, the stability of the structure in the case of the rigid
linkers is generally higher than in the case of the flexible
linkers (i.e., they have lower II). Among the rigid linkers,
the LR5 (Linker-Rigid number 5) with KPKPKP sequence
showed the lowest II, and this linker was selected as the
best linker and used in subsequent analyses.
Modeling of the selected chimeric vaccines
In order to find a suitable model for the desired antigenic
composition, the first step was Blast. Blast results showed
that four templates with 5dlm, 4r8w, 5jw3, 3sdy PDB
codes are most similar to our antigenic composition.
The results of the structural quality survey revealed
that more than 92% of the amino acid residues are in
the favored region in the structure with the linker and
more than 91% in the favored region of the without-
linker structure.
The quality assessment results by ProSA-web server
also demonstrated that for linker-containing structure
and linker-free structure, the Z-Score is − 4.85 and −
4.93, respectively.
Our final models for the chimeric vaccine were shown
in Fig. 1a and b, for MCH and MCH-LR5 structures,
respectively.
Molecular dynamics and free energy calculations
The results of molecular dynamics analysis was shownin
Fig. 2. As shown in Fig. 2a for the MHC, the RMSD
index was 1.4 Å, and for the MHC-LR5 it was 2.02 Å.
Both structures reached equilibrium state in 18 ns. The
RMSD difference between these two structures is negli-
gible, but it can be seen from Fig. 2a that although the
linker has little effect on the structure, it can increase
the flexibility of the structure and modify the relevant
antigen behavior. If these changes are significant, the
natural structure of the protein undergos changes and
can lead to undesirable results. In the case of our anti-
genic proteins, although their structure unlikely to be
completely lost natural state, it potentially can partially
alter the structure of antigens and conformational epi-
topes. In addition, RMSD indexes were calculated separ-
ately for M2e, HA2, and CTxB in relation to each other
(Table 3). The RMSF index was also calculated to inves-
tigate the fluctuations in the structure. This index was
calculated for the MCH-LR4 and MCH structures at 0.5
and 0.51 nm, respectively (Fig. 2b). Similar to the RMSD
index, there was no significant difference in the RMSF
index, but the lower RMSF index of the linker-free
structure indicates higher flexibility of construct contain-
ing linker.
Gyration Radius analysis showed that the MCH struc-
ture had a higher compression rate than the MCH-LR%
structure, which is consistent with the results of the
RMSF index analysis, which displayed increased flexibil-
ity in the structure in which the linker was inserted.
Fig. 1 Chimeric vaccine modeling. 3D model of a) linker-free structure (MCH) and b) linker-containing structure (MCH-LR5)
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The SASA index was also calculated, which was
215.79 (nm2) for the MCH-LR5 structure and 212.2
(nm2) for the MCH, respectively. The results obtained
during the SASA calculation are in agreement with the
outputs of the ROG and show an increase in the water
accessibility level of the structure containing the linker
and a decrease in its compression. Examination of the
secondary structure revealed that there are differences in
the secondary structure between the MCH and MCH-
LR5, as shown in Table 4.
In order to check the stability of the systems after MD,
free energy was estimated by g_mmpbsa, which is an ef-
ficient tool. The results are listed in Table 5. Based on
the outputs of g-mmpbsa, it can be claimed that the
linker can increase the stability of the structure.
Study of epitopes of chimeric vaccine
Linear B cell epitope analysis
Potential linear epitopes in the chimeric vaccine were
examined using the BepiPred server. Six potential epi-
topes less than the threshold (0.5) was found as shown
in Fig. 3. The amino acid sequences of these linear epi-
topes are presented in Table S3. However after confirm-
ation with VaxiJen server with 0.5 threshould (Table S4),
Only three linear epitopes seems to be real epitopes with
significant antigenicity (Table 6). In addition, predicted
epitopes was confirmed with IEDB databases (Table S5).
Conformational and linear epitope analysis by Ellipro server
Both the linear and conformational epitopes for B cells
were examined using the Ellipro server. The complete
modeled antigenic structures (MCH and MCH-LR5),
were analyzed by the server. As listed in Table S9, differ-
ent linear epitopes were found for the MCH and MCH-
LR5 vaccines (Table S6). However, after confirmation by
VaxiJen (Table S7) and IEDB (Table S8), only two epi-
tope predicted as real epitope for MCH, and unfortu-
nately no linear epitope was confirmed for MCH-LR5 by
this server (Table 7). In the case of the conformational
epitopes, 6 and 4 epitopes were found for the MCH and
MCH-LR5 structures respectively. All sequence and in-
formation of the epitopes are listed in Table S9. The
position of the linear and conformational epitopes is
depicted in Fig. 4.
CD4 T cells (MHCII) epitope prediction
NetMHCIIpan 0.4 server (http://www.cbs.dtu.dk/services/
NetMHCIIpan/) was used for prediction of MHCII bind-
ing epitopes. In Table S10, we showed the strong binder
epitopes for seven most frequently MHCII alleles (DRB1_
0701, DRB1_1501, DRB1_0301, DRB3_0101, DRB3_0202,
DRB4_0101, DRB5_0101) for MCH-LR and MCH, re-
spectively. No difference was observed between MHCII
epitopes of MCH and MCH-LR5. In addition, these epi-
topes covered all 7 most frequent alleles of MHCII
molecule.
Prediction of CTL (MHCI) epitopes
CD8 T cells recognize epitopes presented on MHC class
I molecules. The CTLPred and NetMHCIpan 4.01
servers were used to find CTL epitopes. Table 8 and
Table S11 show the information of the epitopes of CTL
cells predicted by NetMHCIpan and CTLpred,
Fig. 2 RMSD and RMSF calculation. Calculated a) RMSD and b) RMSF for modeled structures of chimeric vaccine, MCH (black) and MCH-LR5 (red)
Table 3 RMSD index calculated individually for each antigen in
desired structures
Chimeric vaccine M2e CTxB H2A
MCH and MCH-LR5 3.73 8.56 8.29
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respectively. In Table S12 (for CTLpred) and Table 7
(for NetMHCIpan) MHC Restriction of these epitopes
are also shown.
Codon usage optimization
Four expression hosts including Homo sapiens, Mus
musculus, Saccharomyces cerevisiae and Escherichia coli
were used for codon usage optimization. Optimized
codones for each host listed in Table S13.
Post translational modification prediction
Prediction of post translational modifications (PTMs)
carried out for two vaccine candidates. One O-
glycosylation site was found for MCH-LR5 at site 152.
All possible sites for O-glycosylation were predicted by
the neural network (Figure S1). Nevertheless, for MCH-
LR5 only one site (152) passes the threshold (0.5), and
no O-glycosylation site was found for MCH.
Among five possible N-glycosylation sites, one N-
glycosylation was found in the first N of CTxB protein
at site 56 and site 50 that passed the threshold (0.5) in
MCH-LR5 and MCH, respectively (Figure S2).
Possible phosphorylation PTM in serine, tyrosine and
threonine were shown in Figure S3. No significant differ-
ence was observed in the pattern of phosphorylation be-
tween MCH-LR and MCH.
The solubility of the antigenic fusion protein
The solubility of the complete protein composition, in-
cluding MCH and MCH-LR5, was calculated using
Protein-sol server. The results can be seen in Fig. 5. The
solubility of the MCH-LR5 was calculated to be 0.449,
which is approximately equal to the average of E. coli
proteins. PI of this antigenic compound was 6.04.
In the case of MCH, it was found that the solubility
was higher than the MCH-LR5 (0.536), and its PI was
5.27. These results indicated that the insertion of a
linker (LR5) between antigenic compounds can reduce
the fusion protein’s solubility.
Other in silico physiochemical analysis
Immunogenicity of the antigenic compound for a set of
seven HLA class II alleles
Using the CD4Episcore server, the CD4 T cell immuno-
genicity of M2e-LR5-HA2 antigens was predictes for hu-
man MHC-II (seven HLA alleles [21]). The combined
method and threshold of 50 were used for prediction.
The results of this analysis are shown in Table 9.
Examination of disulfide bonds
This analysis was done by the DIANNA server. The results
of the study of disulfide bonds are shown in Table 10. As
shown, the linker entry changes the position of a disulfide
bond, one of the contributors to this linkage is cysteine 19 in
both structures, but the second contributors in the MCH-
LR5 structure is cysteine 306 and in MCH is cysteine 55.
Proteasome cleavage site analysis
The results of the ProteinCutter digestion site analysis
are presented in Table S14.
Discussion
Large epidemics and pandemics have been documented in
the history of world by various subtypes of the influenza
virus. Even today with the tremendous advances in medi-
cine and biomedical sciences, there is still much concernes
about the occurrence of similar epidemics and pandemics
[22]. Current vaccines against influenza could not induce
long-lasting immunity, so each year, specific vaccine is
produced based on the dominant subtypes for the coming
year [10]. For this reason, it is necessary to produce sub-
unit vaccines using conserved regions of the virus so that
the virus cannot scape frommemorized immune responses
[23]. Studies showed that the influenza virus HA2 (or
stem region) region of HA angigens is more conserved
than it’s globular region (HA1). Therefore, HA2 attracted
considerable interest for developing a universal vaccine
for influenza virus [1]. On the other hand, the M2 antigen
has a fragment in its N-terminal region that is highly con-
served in almost all influenza virus subtypes [24]. The only
disadvantage of M2e is its low immunogenicity, therefore,
needs to be used with adjuvants to improve M2e-based
vaccines immunogenicity [25]. Studies have used multiple
copies M2e and have produced neutralizing antibodies
against this region in immunized animals. In some cases,
very promising results have been obtained against chal-
lenges with different subtypes of virus and observed cross-
protection [5, 7].
Table 4 Secondary structure information and differences between MCH and MCH-LR5 structures
Linker Alpha helix 3–10 helix Pi helix Extend strand Beta bridge turn Bend None
MCH-LR5 112 4 20 49 4 49 47 56
MCH 130 10 0 53 3 50 34 61
Table 5 Free energy outputs of constructs using MM-PBSA
computations
Energy state MCH-LR5 MCH
Potential energy in Vacuum − 5598.57 5208.72
Polar solvation energy (kJ mol) −13,192.5 −12,912.64
Non-polar solvation energy (kJ mol) 515.11 509.628
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In this study, we designed a chimeric subunit vaccine for
the influenza virus using the conserved regions of HA2 and
M2e antigens. As mentioned, because of the low immuno-
genicity of M2e, application of adjuvants is required. There-
fore, in this study, for the first time, four different
immunoadjuvant proteins were used from different organ-
isms. These adjuvants have been used in many studies and
their adjuvanticity have been confirmed. As noted earlier, in
chimeric subunit vaccines or multi-antigenic vaccines
(MAVs), several antigens or epitope fragments are put to-
gether to provide more potent immunogenicity. Due to the
fusion of several fragments together, interference in struc-
tures may affect the 3D structure, stability and half-life of the
vaccine. Therefore, we assessed all combinations of antigens
to find a combination that has most stable and natural state.
Recently, in silico study on HA with another adjuvant called
Mx fused by EAAK linker was carried out [26]. The differ-
ence between our study and the mentioned study is that we
examined different types of adjuvants and selected the best
one, not just one adjuvant, regardless of its effect on the vac-
cine’s structural and physiochemical properties. Secondly, we
did the same for selecting the linker, and we selected the best
linker out of 12 different linkers.
We first combined the two HA2 and M2e antigens in
all possible combinations with ASP-1, CTxB, STxB, and
LTB adjuvants and evaluated their stability and half-life.
Surprisingly, the combination of antigens in all combina-
tions with three out of four adjuvants produced unstable
proteins. In this regard, only CTxB could form a stable
polypeptide in combination with these two antigens.
This result is in line with previous studies that propose
CTxB as an ideal adjuvant for the designing of subunit
vaccines [12, 20, 27]. CTxB is the B subunit of the chol-
era toxin and is responsible for transferring the toxic
subunit (cholera toxin subunit A or CTxA), through the
surface GM1 receptors of mucosal cells into the cell.
CTxB individually does not cause any toxicity to the
cells and cytotoxicity occurs only when CTxA enters the
cell [28]. In this study, we used this adjuvant for two rea-
sons. Firstly, studies showed that the affinity of CTxB to
GM1 receptors, acts as delivering moiety to the cell sur-
face, thus increases cellular uptake efficiency and antigen
presentation [29]. Secondly, the proper stability of this
protein, which can even be administered orally, will in-
crease overall protein stability [30, 31]. It should be
noted that the adjuvant itself, is an antigen of Vibrio
Fig. 3 The schematic diagram for epitope regions of M2e-LR5-HA2 antigens ploted by BepiPred server. Epitopic regions are under the threshold curve
Table 6 Information and sequence of linear epitopes found for
B cells predicted by Bepipred and confirmed by VaxiJen
No Start End Sequence Length
1 5 27 TEVETPTRTGWECNCSGSSDPGL 23
3 79 91 RLIAKTNQQF 13
5 153 183 ENAEEDGTGCFEIFHKCDDNCMASIRNNTYD 31
Jafari et al. BMC Molecular and Cell Biology           (2020) 21:89 Page 7 of 13
cholera, so it can also induce immunization against Vibrio
cholera [32, 33]. However, the primary purpose of this study
was to design a vaccine against influenza so we ignored epi-
tope prediction for CTxB as well as the linker parts.
Linkers as small amino acid sequences are recently used in
the fields of biotechnology, including protein engineering
and production of fusion proteins [34]. In this study, we used
12 different types of linkers, including six flexible and six
rigid linkers between antigenic compounds with CtxB adju-
vant, and examined their stability and half-life. Among these
12 linkers, rigid linkers showed higher stability than flexible
linkers, which can be justified by the fact that flexible linkers
seems to allow antigenic fragments to fluctuation, they cause
a loss of stability [35, 36]. In molecular dynamics analysis,
the results were consistent with these results. Therefore, the
best and most stable form of the chimeric vaccine was ob-
tained when we used the rigid linker with the KPKPKP se-
quence and we called this linker LR5. Since this linker is
rigid, it makes the whole polypeptide structure more stable.
The amino acid proline is also present in other proline
linkers (GPGP [20]), and its advantage is that it interferes
with the regular secondary structures of proteins in fusion
Table 7 Linear epitopes of MCH and MCH-LR5 predicted by Ellipro and confirmed by vaxijen
Vaccine No Start End Sequence Length Score
MCH 1 202 247 LNRLIAKTNOQFELIDNEFNEVEKOIGNVINVVTROSITEVWSYNAE 46 0.829
2 68 103 DKIFSYTESLAGKREMAIITFKNGAIFQVEVPGSQH 36 0.741
MCH-LR5 No epitope confirmed by VaxiJen for vaccine containing linker. For details of predicted linear epitopes please see Table S9.
Fig. 4 Position of the linear and conformational epitopes of chimeric vaccines. Linear epitopes showed for a) MCH (linker free) and b) MCH-LR5
(linker-containing) structures of chimeric vaccine. Conformational epitopes showed for c) MCH and d) MCH-LR chimeric vaccines. The regions
showed by yellow color specify the epitopic regions
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sites. Finally, by selecting this linker and CTxB adjuvant, we
used the final construct containing M2e-LR5-CTxB-LR5-
HA2 for structural analysis.
Using the combination of homology modeling and ab
initio method in protein structure prediction, the 3D
structure of the chimeric vaccine was modeled, and mo-
lecular dynamics simulations were performed. By com-
paring the RMSD and RMSF indexes, it was found that
insertion of the linker between antigens caused little
changes in the structure of the vaccine, which was negli-
gible. Therefore, it is unlikely that this linker will cause
significant alterations in the overall structure of the vac-
cine to disrupt their conformational epitopes.
To investigate epitopes, we mapped linear and conform-
ational epitopes using several tools. Since more than 90% of
B cell epitopes are conformational epitopes, these epitopes
are critical. We used Bepipredb and Ellipro servers to deter-
mine both linear and conformational epitopes. In adddtion,
CD4 and CTLs epitopes were also predicted. CD4 epitopes
covered all seven most frequent alleles of MHCII molecule.
Finally, we analyzed the protein disulfide bond sites, solubil-
ity, and immunogenicity using different tools. Codon
optimization carried out for four different expression hosts
for heterologous protein expression. In addition, PTMs also
were predicted for candidate chimeric vaccine. Disulfide
bonds and PTMs pattern of this candidate vaccine suggest
that the best host choice for protein expression is mamma-
lian cell lines.
Eventually, our results showed that this combination of
HA2, M2e, and CtxB could be a suitable candidate
chimeric vaccine for further analysis through in vitro and
in vivo experiments.
Conclusions
There are several points to consider when concluding
this study. First, although bioinformatics tools have been
Table 8 Predicted epitopes for MHC class I by NetMHCIpan for MCH and MCH-LR
Number Epitope HLA Class I allele Core Score_EL %Rank Bind Level
1 YLTEAKVEKLCV HLA-A*02:01 YLTEAKVEV 0.1005680 1.878 WB
2 RMKDTLRIAYL HLA-A*02:01 RMKDTIAYL 0.1528500 1.411 WB
3 LLIAMENQHTI HLA-A*02:01 LLMENQHTI 0.2700590 0.855 WB
4 KLSSGYKDVIL HLA-A*02:01 KLSSGDVIL 0.1173450 1.671 WB
5 KLKFGVFFTV HLA-A*02:01 KLFGVFFTV 0.3885330 0.553 WB
6 TLNDKIFSYT HLA-A*02:01 TLNDKIFYT 0.1308210 1.551 WB
7 TLRIAYLTEA HLA-A*02:01 TLIAYLTEA 0.1362920 1.512 WB
8 YLTEAKVEKL HLA-A*02:01 YLTEAVEKL 0.6496180 0.233 SB
9 GLFGAIAGFI HLA-A*02:01 GLFGAIAFI 0.1650370 1.323 WB
10 ELIDNEFNEV HLA-A*02:01 ELIDNEFEV 0.1867090 1.205 WB
11 KLYERVKRQL HLA-A*02:01 KLYERVKQL 0.3265950 0.689 WB
12 TLNDKIFSY HLA-A*02:01 TLNDKIFSY 0.1792230 1.243 WB
13 KIFSYTESL HLA-A*02:01 KIFSYTESL 0.7627700 0.134 SB
14 GLFGAIAGF HLA-A*02:01 GLFGAIAGF 0.1582900 1.373 WB
15 GLIDGWYGF HLA-A*02:01 GLIDGWYGF 0.2246050 1.028 WB
16 AIDQITGKL HLA-A*02:01 AIDQITGKL 0.1138960 1.708 WB
17 LIDNEFNEV HLA-A*02:01 LIDNEFNEV 0.4518310 0.457 SB
18 IAMENQHTI HLA-A*02:01 IAMENQHTI 0.2537330 0.911 WB
19 KLSSGYKDV HLA-A*02:01 KLSSGYKDV 0.0969210 1.929 WB
WB Weak binders, SB Strong Binders
Fig. 5 The solubility of antigenic composition (QuerySol column:
predicted column), a) for the linker-containing mode and b) without
the linker, compared to the average solubility of the E. coli proteins
(PopAvrSol column)
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used in the last two decades to help researchers in the med-
ical and biological sciences, it should be noted that these
tools can bring us closer to a goal and they do not provide
a definite result. So our research needs to be confirmed in
subsequent in vivo experiments. However, this in silico
study showed that the two antigens M2e and HA2 can be
fused with CTxB by a rigid linker, and this fusion occurs
without affecting the stability and vaccine’s 3D structure.
Therefore, in the next phase of this study, vaccine’s opti-
mized sequence can be molecularly cloned into an expres-
sion vector to express the protein in mammalian cells and
investigate its immunogenicity in animals.
Methods
Retrieving and evaluating the antigenic sequences
Nucleic acid and protein sequences for the M2 and HA
antigens for Influenza A virus (A/chicken/Fujian/SD180/
2017(H7N9)) were retrieved from the Nucleotide data-
base at NCBI and analyzed using Snapgene software
(https://www.snapgene.com/). Highly antigenic frag-
ments of M2 and HA regions were identified as M2e
and HA2 through literature review and their amino acid
sequence was used for analysis.
Sequences of several adjuvants were also obtained
from the same database and used in subsequent ana-
lyses. These adjuvants were CTxB (Vibrio cholera) [12],
ASP-1 (Onchocerca volvulus) [37], LTB (Escherichia coli)
[38], and STxB (Shigella dysenteriae) [39] that recent
studies have shown their mucosal immunoadjuvant po-
tential. Protein sequences of antigenic components and
adjuvants listed in Table S1.
Analyzing the different fusion proteins
In order to construct a chimeric vaccine from M2e and
HA2 antigens with a suitable adjuvant, different combi-
nations of these proteins were made and analyzed by
ProtParam server (https://web.expasy.org/protparam/) to
evaluate stability and half-life of resulting fusion
proteins.
Linker selection
In a chimeric vaccine that combines several different
protein fragments, linkers act as separators and needed
for maintaining the three-dimensional structure of fu-
sion protein. In this research, various linkers were se-
lected from previous studies. Each of these linkers was
placed among the antigens selected in the previous step
and analyzed by ProtParam server, and the best linker
was selected regarding the stability and half-life of the
fusion proteins.
Three dimensional structure modeling
We selected a combination of antigens from the previ-
ous analysis with best types of linker and adjuvant as the
final construct. In order to investigate the structural
variation and the effect of the linker on the antigens’
structure, the chimeric vaccines’ three-dimensional
structures was modeled. For this purpose, Modeller soft-
ware version 9.21 was used to construct the three-
dimensional structure of M2e-L-HA2-L-CTxB (L repre-
sents linker) and M2e-HA2-CTxB. This software per-
forms homology-based modeling using BLAST. In the
first step, to find an appropriate template for our protein
structure, BLAST search was performed. As predictable
for complex constructs, for some regions of the antigen,
structure of the desired template was not found. For this
purpose, the Quark server was used to model these areas
using the ab initio strategy. Finally, the structures de-
rived from Modeller and Quark software were assembled
using PyMod software and the final model was created.
Model quality assessment
After the modeling of the structure, the quality of the
models was examined. In this regard, the phi (Φ) and psi
(ψ) torsion were analyzed by the rampage server. The
PROSA-web server was also used to analyze the model
quality further.
Table 9 Immunogenicity of the antigenic compound (M2e-LR5-HA2) for 7 alles of HLA class II



























111 125 90.9629 ITEVWS
YNA
26.56 13.18 5.61 18.8 43.07 78.93 16.56
2 AMQN
RIQJDPVKLSS
191 205 93.6562 RIQI
DPVKL
0.02 38.96 24.19 0.97 4.53 5.15 13.28
Table 10 Results of disulfide bonds analysis of linker-free and
linker-containing structures by DIANNA 1.1 Server
Number Location Sequence
MCH-LR5 1 17–299 RTGWECNCSGSEDGTGCFEIFH
2 19–306 GWECNCSGSSDEIFHKCDDNCM
3 138–310 KVEKLCVWNNKKCDDNCMASIR
MCH 1 17–287 RTGWECNCSGSEDGTGCFEIFH
2 19–55 GWECNCSGSSDNITDLCAEYHN
3 132–294 KVEKLCVWNNKEIFHKCDDNCM
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Molecular simulation and free energy calculations
Molecular dynamics analysis was performed by Gromacs
software 2019.1 in 100 ns to analyze structural stability
and structural variations in the model due to the linker
addition. To begin this analysis, the topology for both
structures (vaccines with and without linker), was first
generated by the amber03 force field. Subsequently, the
structures were placed inside a Tip3 water box. In the
next step, for neutralization of the system, ionization
carried out using CL− and NA+ ions at a concentration
of 0.15M. Minimization for the system was performed
by the Steepest descent minimization method. In the
equilibration process, the NVT and NPT steps were
taken to couple system to desired temperature and pres-
sure (here 310 K and 1 bar). In the NVT and NPT steps,
the V-rescale method and Berendsen method were used,
and the time taken to perform these two steps was 200
and 600 ps, respectively. After completing the molecular
dynamic step, root-mean-square deviation (RMSD)
index was calculated for both structures (with and with-
out linker) to investigate structural changes. The second-
ary structure was also analyzed to investigate possible
changes in this structure with and without linkers. The
radius of gyration (ROG) and root mean score of fluctu-
ation (RMSF) indexes were used to analyze protein fold-
ing and level of fluctuations to investigate further
changes induced by the addition of a linker in the struc-
ture of antigens. In the present study using g_mmpbsa
module of gromacs, free energy was calculated for our
constructs. The free energy calculation procedure by g-
mmpbsa comprises three steps. At first potential energy
in vacuum is calculated, and then polar, and non-polar
solvation energies were computed. For non-polar solv-
ation energy calculation, the solvent-accessible surface
area (SASA) model was employed.
Study of epitopes in the chimeric vaccine
In order to map epitopic regions as well as their anti-
genic quality in a vaccine, in vitro and in vivo experi-
ments are necessary. However, bioinformatics has
provided some tools that help to identify and analyze
epitopes and antigenic states of a designed vaccine. In
this study, bioinformatics tools were used to recognize
humoral and cellular immune system epitopes for the
designed chimeric vaccine. As previous studies have
shown, many bioinformatics tools can map epitopes on
B cells, T cells, and CTLs. Epitopes are classified into
two main types of linear and conformational epitopes,
we investigated both types of epitopes in this study. Lin-
ear epitopes, as the name implies, are epitopes that exist
in a continuous sequence and can be easily screened by
a series of software and servers using antigen or vaccine
sequences. However, the most important type of epi-
topes, especially in studies requiring the induction of
neutralizing antibodies, are conformational epitopes that
may be composed of a set of long-distance amino acids.
Therefore, for the investigation and mapping of these
epitopes, it is necessary to predetermine the exact and
high-resolution structure of the 3D antigen or vaccine
by the modeling software.
Linear epitope prediction for B cells
Bepipred 2.0 server (http://www.cbs.dtu.dk/services/
BepiPred/), was used to investigate linear epitopes of B
cells. The threshold used for prediction on this server
was set to 0.5.
Conformational epitopes of B cell
The Ellipro server (http://tools.iedb.org/ellipro/) can pre-
dict the conformational epitopes for antibodies using the
3D structure. The PDB file created by the modeling
method was given to the server as an input for both with
(MCH-LR5) and without linker (MCH) structures. It
should be noted that in this server, we had to remove
water molecules from the structure, so the water mole-
cules were removed from the model. The software set-
tings were set by default to 0.5 for minimum score and 6
for maximum distance.
MHC class I and class II epitope prediction
Epitopes related to CTL cells (MHCI) were examined
using the CTLPred server (http://crdd.osdd.net/raghava/
ctlpred/) and NetMHCIpan 4.01 server (http://www.cbs.
dtu.dk/services/NetMHCpan/). NetMHCIpan server uses
ANN for prediction of molecules binding to any HLA
class I molecules. In this analysis 8–11 aa was selected
for the length of epitopes. In addition class I HLA
super-type alleles were used for epitope prediction. The
maximum %rank for weak and strong binders set as 2
and 0.5, respectively.
As CD4 T cell recognizes epitopes presented on
MHCII molecules, NetMHCIIpan 0.4 server (http://
www.cbs.dtu.dk/services/NetMHCIIpan/) was used for
prediction of MHCII binding epitopes. This server uses
ANN for prediction of any 15 aa length of a protein se-
quence that binds to any MHC II alleles. For strong
binders we set the %rank < 2 and for weak binders < 10.
Strong binders for seven most frequently MHCII alleles
(DRB1_0701, DRB1_1501, DRB1_0301, DRB3_0101,
DRB3_0202, DRB4_0101, DRB5_0101) were predicted.
Codon usage optimization for heterologous expression of
designed chimeric vaccine candidate
Codon usage for MCH-LR5 as the candidate vaccine
was optimized with Jcat server (http://www.jcat.de/).
Four expression hosts including Homo sapiens, Mus
musculus, Saccharomyces cerevisiae and Escherichia coli
were used for codon usage optimization.
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Post translational modification analysis
Prediction of post translational modifications (PTMs)
carried out for two vaccine candidates. NetOglyc4.0 ser-
ver (http://www.cbs.dtu.dk/services/NetOGlyc/) used for
prediction of O-glycosylation sites and NetNglyc1.0 ser-
ver (http://www.cbs.dtu.dk/services/NetNGlyc/) used for
prediction of N-glycosylation sites. In addition, for pre-
diction of potential phosphorylation sites in vaccine, we
used NetPhos 3.1 server (http://www.cbs.dtu.dk/services/
NetPhos/). We performed the phosphorylation for
serine, tyrosine and threonine residues.
Other analysis of the chimeric vaccine candidate
Proteasome cleavage sites
Digestion sites for proteinases and chemicals were deter-
mined by the PeptideCutter server (https://web.expasy.
org/peptide_cutter/) from Expasy. The server identifies
and provides all possible cleavage sites for various types
of proteinases and peptidases as well as chemicals.
In addition to PeptideCutter, probable cleavage sites
for the proteasome were investigated using the
NetChop3.1 server (http://www.cbs.dtu.dk/services/
NetChop/). The settings used in this server were in the
C-terminal sequence analysis method with a threshold
of 0.5.
Immunogenicity of the chimeric vaccine
The CD4Episcore server (http://tools.iedb.org/CD4epi-
score/) was used for this purpose. To compare the effect
of the presence or absence of the linker on the immuno-
genicity of the vaccine, we used complete sequences of
the MCH-LR5 and MCH vaccines.
Solubility of the chimeric vaccine
The Protein-sol server (https://protein-sol.manchester.
ac.uk/) was used to check the protein solubility when
expressed in an organism. Experimental data show that
the solubility of most E. coli proteins is an average of
0.45. Therefore, if the protein solubility is higher than
0.45, it is likely to be more soluble than E. coli proteins
[40]. This server needs to receive a sequence from the
user (in FASTA format) to identify the protein solubility
with its computational algorithms.
Disulfide bonds analysis
We used the DIANNA server (http://clavius.bc.edu/~
clotelab/DiANNA/) for checking disulfide bonds. This
server can identify the disulfide bonds of a protein in
the following four steps: a) Performs a PSI-Blast to
find similar patterns in databases, b) Using the PSIP
RED server, models the secondary structure of the
protein, c) Predicts the oxidized state of cysteines, d)
Using a neural network algorithm (NN), determines
the disulfide bonds [41].
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